Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Net Income (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Net Income for 9 consecutive years, with -$128.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 12.0% to -$128.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$512.4 million, a 21.23% decrease, with the full-year FY2025 number at -$512.5 million, down 21.23% from a year prior.
  • Net Income was -$128.4 million for Q4 2025 at Denali Therapeutics, down from -$126.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $183.4 million in Q2 2023 to a low of -$133.0 million in Q1 2025.
  • A 5-year average of -$85.7 million and a median of -$100.6 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: soared 398.46% in 2023, then tumbled 154.0% in 2024.
  • Denali Therapeutics' Net Income stood at -$75.3 million in 2021, then tumbled by 31.11% to -$98.7 million in 2022, then tumbled by 34.38% to -$132.6 million in 2023, then grew by 13.51% to -$114.7 million in 2024, then dropped by 12.0% to -$128.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Net Income are -$128.4 million (Q4 2025), -$126.9 million (Q3 2025), and -$124.1 million (Q2 2025).